Current status and prospects of neoadjuvant andconversion therapy for pancreatic cancer

Pancreatic cancer has a low surgical resection rate and a very poor prognosis. In recent years,with the emergence of new drugs, the diversification of treatment methods, the development of multidisciplinarydiagnosis and treatment models, neoadjuvant treatment and translational treatment of pancreatic cancer haveattracted widespread attention. This article systematically sorts out the clinical application of neoadjuvant therapyand translational therapy in pancreatic cancer, as well as the timing of surgery after translational therapy, and proposes to divide resectable pancreatic cancer into low-risk groups and high-risk groups. Patients in the low-riskgroups are recommended to prioritize surgical resection. The high-risk groups and patients with borderlineresectable pancreatic cancer have a lower rate of R0 resection. Neoadjuvant therapy can significantly increase therate of R0 resection. For patients with unresectable pancreatic cancer, a comprehensive assessment should be madeon whether conversion therapy can be performed, and radical surgery is feasible for some effective patients.However, there is no consensus on the selection of neoadjuvant treatment and translational treatment for pancreaticcancer, the treatment cycle, and postoperative adjuvant options. It is believed that with the emergence of highlevel evidence-based medicine, neoadjuvant therapy and conversion therapy will be more widely used in thetreatment of pancreatic cancer.